Table 1.
Effects of MEK inhibitors on drugs-induced behaviors
| Drugs | MEK inhibitors (dose, area) | Behavioral effects | References |
|---|---|---|---|
| None | SL327 (50 mg/kg, i.p.) | ↑ basal locomotor activity | 152 |
| SL327 (50–100 mg/kg, i.p.) | ↓ basal locomotor activity | 92,156,254,255 | |
| PD98059 (50 μM, continuous infusion into the PFC) | ↑ basal locomotor activity↓ | 154 | |
| Cocaine | SL327 (50 mg/kg, i.p.) | ↓ acute cocaine-induced locomotion | 78 |
| SL327 (30 mg/kg, i.p.); PD98059 (10 μM, VTA) | ↓ development of locomotor sensitization (inhibitors were injected/infused before each cocaine injection) | 92,94 | |
| SL327 (40 mg/kg, i.p.); PD98059 (2 μg) or U0126 (1 μg, NAc) | ↓ expression of locomotor sensitization (inhibitors were injected/infused before cocaine challenge) | 80,93 | |
| SL327 (30 mg/kg, i.p.) | ↓ conditioned locomotor response (inhibitor was injected before each cocaine injection during conditioning) | 92 | |
| SL327 (50 mg/kg, i.p.); U0126 (0.1 μg, VTA) | ↓ development of CPP (inhibitors injected/infused before each cocaine injection during conditioning) | 78,100 | |
| U0126 (1 μg, NAc core) | ↓ expression of CPP (inhibitor was infused before CPP test) | 107 | |
| SL327 (30 mg/kg, i.p.); PD98059 (2 μg ) or U0126 (1 μg, NAc core); U0126 (1 μg, BLA) | ↓ context- and cocaine priming-induced expression of CPP and ↓ context-induced reinstatement after SA by impairing memory reconsolidation (inhibitors were injected/infused either before or after reconsolidation phase) |
82,107,112,113 | |
| U0126 (1 μg, CeA) | ↓ context+cues-induced relapse after abstinence from SA (inhibitor was infused before relapse testing) | 116 | |
| U0126 (1 μg, VTA) | ↓ BDNF/GDNF-enhanced relapse by context+cues after abstinence from SA (infusions were conducted immediately after the end of the last SA session) | 118,119 | |
| U0126 (0.5 μg, dmPFC) | ↓ BDNF’s inhibitory effect on context-, cues- and cocaine priming-induced drug seeking after abstinence/extinction of SA (infusions were conducted immediately after the end of the last SA session) | 121 | |
| Amphetamine | SL327 (50–100 mg/kg, i.p.) | ↓ acute amphetamine-induced locomotion | 78,140,141 |
| PD98059 (50 μM, continuous infusion into the PFC) | ↑ acute amphetamine-induced locomotor activity | 154 | |
| SL327 (40 mg/kg, i.p.) | ↓ expression of locomotor sensitization (inhibitors were injected/infused before amphetamine challenge) | 80 | |
| SL327 (30 mg/kg, i.p.) | ↓ conditioned locomotor response (inhibitor was injected before each amphetamine injection during conditioning) | 92 | |
| PD98059 (2.5 μg, NAc ) | ↓ development of intra-NAc amphetamine-induced CPP (inhibitor was infused before or after each intra-NAc amphetamine infusion during conditioning) | 160 | |
| PD98059 (2 μg, NAc ) | ↓ expression of amphetamine-CPP (inhibitor was infused before CPP testing) | 180 | |
| Marijuana (THC) | SL327 (50 mg/kg, i.p.) | ↓ development of THC-induced locomotion tolerance ( inhibitor was injected before each THC administration) | 200 |
| SL327 (50 mg/kg, i.p.) | ↓ development of THC-CPP (inhibitor was injected before each conditioning session) | 196 | |
| Alcohol | PD98059 (30 or 90 μg, i.c.v ) | ↓ development of ACD-CPP (inhibitor was infused before each conditioning session) | 253 |
| SL327 (30 mg/kg, i.p.) | ↑ ethanol SA (inhibitor was injected before SA session) | 255 | |
| U0216 (0.5 μg, VTA) | ↓ GDNF’s inhibitory effect on ethanol SA (infusions were conducted before SA session) | 259 |
i.p. = intraperitoneal injection; i.c.v = intracerebroventricular infusion; ↑ = enhancing effect; ↓ = inhibiting effect